From the Department of Neurology (D.R., A.J.L.), Duke University School of Medicine, Durham; and Department of Surgery (B.A.Z.), Duke University, Durham, NC.
Neurology. 2024 Dec 24;103(12):e210125. doi: 10.1212/WNL.0000000000210125. Epub 2024 Nov 25.
A 77-year-old woman with a medical history of amnestic mild cognitive impairment on lecanemab presented to the hospital with new onset shortness of breath. ECG revealed new diagnosis of atrial fibrillation with rapid ventricular response. Considering the patient's risk factors with a CHADS-VASc score of 6, the patient would warrant use of anticoagulation, with the caveat that this is currently not recommended with use of lecanemab. In this case, we describe the management dilemma posed by new diagnosis of atrial fibrillation using anti-amyloid immunotherapies and suggest possible solutions in this unique population.
一位 77 岁女性,有遗忘型轻度认知障碍病史,因新发呼吸急促就诊。心电图显示新发快速性心房颤动伴心室反应。考虑到患者的危险因素(CHADS-VASc 评分为 6 分),患者需要抗凝治疗,但目前不建议在使用 Lecanemab 的情况下使用。在这种情况下,我们描述了使用抗淀粉样蛋白免疫疗法新诊断心房颤动带来的管理困境,并为这一特殊人群提出了可能的解决方案。